Estudio sobre los efectos anticancerígenos de la melatonina en tumore de pulmón (NSCLC) y sus posibles aplicaciones terapéuticas

En este estudio, publicado en Oncotarget, han sido analizados, con resultados positivos, los efectos anticancerígenos de la melatonina sobre el cáncer de pulmón de células no pequeñas. El cáncer de pulmón no microcítico (NSCLC) también se denomina adenocarcinoma o carcinoma de células escamosas. Según la Sociedad Americana del Cáncer (ACS), es el cáncer de pulmón más común, que corresponde al 85-90% de todos los cánceres de pulmón diagnosticados (datos de ACS, 2012). No está creciendo tan rápidamente como el carcinoma de células pequeñas.

Melatonin as a potential anticarcinogen for non-small-cell lung cancer.

Oncotarget. 2016 Apr 18;

Authors: Ma Z, Yang Y, Fan C, Han J, Wang D, Di S, Hu W, Liu D, Li X, Reiter RJ, Yan X

Non-small-cell lung cancer (NSCLC) is a leading cause of death from cancer worldwide. Melatonin, an idoleamine discovered in the pineal gland, exerts pleiotropic anticancer effects against a variety of cancer types. In particular, melatonin may be an important anticancer drug in the treatment of NSCLC. Herein, we review the correlation between the disruption of the melatonin rhythm and NSCLC incidence; we also evaluate the evidence related to the effects of melatonin in inhibiting lung carcinogenesis. Special focus is placed on the oncostatic effects of melatonin, including anti-proliferation, induction of apoptosis, inhibition of invasion and metastasis, and enhancement of immunomodulation. We suggest the drug synergy of melatonin with radio- or chemotherapy for NSCLC could prove to be useful. Taken together, the information complied herein may serve as a comprehensive reference for the anticancer mechanisms of melatonin against NSCLC, and may be helpful for the design of future experimental research and for advancing melatonin as a therapeutic agent for NSCLC.

PMID: 27102150 [PubMed - as supplied by publisher]

Key Melatonin